1
|
Şuta LM, Ridichie A, Ledeţi A, Temereancă C, Ledeţi I, Muntean D, Rădulescu M, Văruţ RM, Watz C, Crăineanu F, Ivan D, Vlase G, Stelea L. Host-Guest Complexation of Itraconazole with Cyclodextrins for Bioavailability Enhancement. Pharmaceutics 2024; 16:560. [PMID: 38675221 PMCID: PMC11054515 DOI: 10.3390/pharmaceutics16040560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Revised: 04/09/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
Itraconazole is an antifungal agent included in the triazole pharmacological classification that belongs to the BCS class II, characterized by a low solubility in an aqueous medium (of 1 ng/mL, at neutral pH), which is frequently translated in a low oral bioavailability but with a high permeability. In this sense, it is necessary to find solutions to increase/improve the solubility of itraconazole in the aqueous environment. The main purpose of this study is the preparation and analysis of five different guest-host inclusion complexes containing intraconazole. Initially, a blind docking process was carried out to determine the interactions between itraconazole and the selected cyclodextrins. The second step of the study was to find out if the active pharmaceutical ingredient was entrapped in the cavity of the cyclodextrin, by using spectroscopic and thermal techniques. Also, the antifungal activity of the inclusion complexes was studied to examine if the entrapment of itraconazole influences the therapeutic effect. The results showed that the active substance was entrapped in the cavity of the cyclodextrins, with a molar ratio of 1:3 (itraconazole-cyclodextrin), and that the therapeutic effect was not influenced by the entrapment.
Collapse
Affiliation(s)
- Lenuţa-Maria Şuta
- Advanced Instrumental Screening Center, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (L.-M.Ş.); (A.L.); (I.L.); (D.I.)
- Department II—Pharmaceutical Technology, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
| | - Amalia Ridichie
- Advanced Instrumental Screening Center, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (L.-M.Ş.); (A.L.); (I.L.); (D.I.)
- Faculty of Industrial Chemistry and Environmental Engineering, University Politehnica Timisoara, 2 Victoriei Square, 300006 Timisoara, Romania
| | - Adriana Ledeţi
- Advanced Instrumental Screening Center, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (L.-M.Ş.); (A.L.); (I.L.); (D.I.)
| | - Claudia Temereancă
- Faculty of Industrial Chemistry and Environmental Engineering, University Politehnica Timisoara, 2 Victoriei Square, 300006 Timisoara, Romania
| | - Ionuţ Ledeţi
- Advanced Instrumental Screening Center, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (L.-M.Ş.); (A.L.); (I.L.); (D.I.)
- Faculty of Industrial Chemistry and Environmental Engineering, University Politehnica Timisoara, 2 Victoriei Square, 300006 Timisoara, Romania
| | - Delia Muntean
- Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (D.M.); (M.R.); (F.C.); (L.S.)
| | - Matilda Rădulescu
- Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (D.M.); (M.R.); (F.C.); (L.S.)
| | - Renata-Maria Văruţ
- Faculty of Pharmacy, University of Medicine and Pharmacy Craiova, 2-4 Petru Rares Str., 200349 Craiova, Romania;
| | - Claudia Watz
- Department I—Pharmaceutical Physics, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania;
| | - Florentin Crăineanu
- Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (D.M.); (M.R.); (F.C.); (L.S.)
| | - Denisa Ivan
- Advanced Instrumental Screening Center, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (L.-M.Ş.); (A.L.); (I.L.); (D.I.)
| | - Gabriela Vlase
- Research Centre for Thermal Analysis in Environmental Problems, West University of Timisoara, Pestalozzi Street 16, 300115 Timisoara, Romania;
| | - Lavinia Stelea
- Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (D.M.); (M.R.); (F.C.); (L.S.)
| |
Collapse
|
2
|
Nunes PD, Pinto JF, Bauer-Brandl A, Brandl M, Henriques J, Paiva AM. In vitro dissolution/permeation tools for amorphous solid dispersions bioavailability forecasting I: Experimental design for PermeaLoop™. Eur J Pharm Sci 2023; 188:106512. [PMID: 37423576 DOI: 10.1016/j.ejps.2023.106512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 06/11/2023] [Accepted: 06/29/2023] [Indexed: 07/11/2023]
Abstract
Along with the increasing demand for candidate-enabling formulations comes the need for appropriate in vitro bioavailability forecasting. Dissolution/permeation (D/P) systems employing cell-free permeation barriers are increasingly gaining interest, due to their low cost and easy application as passive diffusion bio-predictive profiling in drug product development, as this accounts for nearly 75% of new chemical entities (NCEs) absorption mechanism. To this end, this study comprises theoretical considerations on the design and experimental work towards the establishment and optimization of a PermeaLoop™ based dissolution/permeation assay to simultaneously evaluate the drug release and permeation using Itraconazole (ITZ)-based amorphous solid dispersions (ASD) formulations, with different drug loads, based on a solvent-shift approach. Alternative method conditions were tested such as: donor medium, acceptor medium and permeation barrier were screened using both PermeaPad® and PermeaPlain® 96-well plates. A range of solubilizers, namely Sodium Dodecyl Sulfate, Vitamin E-TPGS and hydroxypropyl-β-cyclodextrin, were screened as possible solubilizing additives to the acceptor medium, while donor medium was varied between blank FaSSIF (phosphate buffer) and FaSSIF. The method optimization also included the ITZ dose selection, being the ITZ single dose (100 mg) considered the most adequate to be used in further experiments to allow the comparison with in vivo studies. In the end, a standardized approach that may be applied to predict the bioavailability of weakly basic poorly soluble drug-based formulations is described, contributing to strengthening the analytical portfolio of in vitro pre-clinical drug product development.
Collapse
Affiliation(s)
- Patrícia D Nunes
- R&D Analytical Development, Hovione Farmaciência S.A., Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal; R&D Oral Drug Product Development, Hovione Farmaciência S.A., Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal; Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal
| | - João F Pinto
- Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
| | - Annette Bauer-Brandl
- Drug Transport and Delivery Group, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense DK, 5230, Denmark
| | - Martin Brandl
- Drug Transport and Delivery Group, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense DK, 5230, Denmark.
| | - João Henriques
- R&D Oral Drug Product Development, Hovione Farmaciência S.A., Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal
| | - Ana Mafalda Paiva
- R&D Analytical Development, Hovione Farmaciência S.A., Campus do Lumiar, Building S, 1649-038 Lisboa, Portugal
| |
Collapse
|
3
|
Moens F, Vandevijver G, De Blaiser A, Larsson A, Spreafico F, Augustijns P, Marzorati M. The Dynamic Intestinal Absorption Model (Diamod®), an in vitro tool to study the interconnected kinetics of gastrointestinal solubility, supersaturation, precipitation, and intestinal permeation processes of oral drugs. Int J Pharm X 2023. [DOI: 10.1016/j.ijpx.2023.100177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023] Open
|
4
|
Cuoco A, Eriksen JB, Luppi B, Brandl M, Bauer-Brandl A. When interactions between bile salts and cyclodextrin cause a negative food effect: Dynamic dissolution/permeation studies with itraconazole (Sporanox®) and biomimetic media. J Pharm Sci 2022; 112:1372-1378. [PMID: 36539063 DOI: 10.1016/j.xphs.2022.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 12/14/2022] [Accepted: 12/14/2022] [Indexed: 12/23/2022]
Abstract
The marketed oral solution of itraconazole (Sporanox®) contains 40% (259.2 mM) of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD). The obvious role of HP-β-CD is to solubilize itraconazole and to overcome its poor aqueous solubility that restricts its absorption. In this study, we investigated the biorelevance of in vitro experiments by the influence of biomimetic media (containing bile salts and phospholipids) on the predicted itraconazole absorption from the commercial HP-β-CD-based Sporanox® solution. We performed phase-solubility studies of itraconazole and dynamic 2-step-dissolution/permeation studies using a biomimetic artificial barrier, Sporanox® solution, and fasted state simulated intestinal fluid (FaSSIF_V1). Both FaSSIF_V1 and HP-β-CD increased the apparent solubility of itraconazole when used individually. In combination, their solubility-enhancing effects were not additive probably due to the competition of bile salts with itraconazole for the hydrophobic cavity of HP-β-CD. Our combined dissolution/permeation experiments indicated the occurrence of a transient supersaturation from Sporanox® upon two-step dissolution. Through systematic variation of bile salt concentrations in the biomimetic media, it was observed that the extent and the duration of supersaturation depend on the concentrations of bile salts: supersaturation was rather stable in the absence of bile salts and phospholipids. The higher the bile salt concentration, the faster the collapse of the transient supersaturation occurred, an effect which is nicely mirrored by reduced in vitro permeation across the barrier. This is an indication of a negative food effect, which in fact correlates well with what earlier had been observed in clinical studies for Sporanox® solution. In essence, we could demonstrate that in vitro two-stage dissolution/permeation experiments using an artificial barrier and selected biomimetic media may predict the negative effects of the latter on cyclodextrin-based drug formulations like Sporanox® Oral Solution and, at the same time, provide a deeper mechanistic insight.
Collapse
Affiliation(s)
- Arianna Cuoco
- Department of Physics Chemistry and Pharmacy, University of Southern Denmark, Odense M, Denmark; Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy
| | | | - Barbara Luppi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy
| | - Martin Brandl
- Department of Physics Chemistry and Pharmacy, University of Southern Denmark, Odense M, Denmark
| | - Annette Bauer-Brandl
- Department of Physics Chemistry and Pharmacy, University of Southern Denmark, Odense M, Denmark.
| |
Collapse
|
5
|
Hens B, Gonzalez-Alvarez I, Bermejo M. Exploring the Predictive Power of the In Situ Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. Mol Pharm 2022; 19:749-762. [DOI: 10.1021/acs.molpharmaceut.1c00861] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Bart Hens
- Drug Product Design, Pfizer, Sandwich, Kent, CT13 9NJ, United Kingdom
| | - Isabel Gonzalez-Alvarez
- Department Engineering Pharmacy Section, Miguel Hernandez University, San Juan de Alicante, 03550 Alicante, Spain
| | - Marival Bermejo
- Department Engineering Pharmacy Section, Miguel Hernandez University, San Juan de Alicante, 03550 Alicante, Spain
| |
Collapse
|
6
|
Lee JH, Park C, Weon KY, Kang CY, Lee BJ, Park JB. Improved Bioavailability of Poorly Water-Soluble Drug by Targeting Increased Absorption through Solubility Enhancement and Precipitation Inhibition. Pharmaceuticals (Basel) 2021; 14:ph14121255. [PMID: 34959655 PMCID: PMC8707685 DOI: 10.3390/ph14121255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 11/27/2021] [Accepted: 11/29/2021] [Indexed: 11/16/2022] Open
Abstract
Itraconazole (ITZ) is a class II drug according to the biopharmaceutical classification system. Its solubility is pH 3-dependent, and it is poorly water-soluble. Its pKa is 3.7, which makes it a weak base drug. The aim of this study was to prepare solid dispersion (SD) pellets to enhance the release of ITZ into the gastrointestinal environment using hot-melt extrusion (HME) technology and a pelletizer. The pellets were then filled into capsules and evaluated in vitro and in vivo. The ITZ changed from a crystalline state to an amorphous state during the HME process, as determined using DSC and PXRD. In addition, its release into the gastrointestinal tract was enhanced, as was the level of ITZ recrystallization, which was lower than the marketed drug (Sporanox®), as assessed using an in vitro method. In the in vivo study that was carried out in rats, the AUC0-48h of the commercial formulation, Sporanox®, was 1073.9 ± 314.7 ng·h·mL-1, and the bioavailability of the SD pellet (2969.7 ± 720.6 ng·h·mL-1) was three-fold higher than that of Sporanox® (*** p < 0.001). The results of the in vivo test in beagle dogs revealed that the AUC0-24h of the SD-1 pellet (which was designed to enhance drug release into gastric fluids) was 3.37 ± 3.28 μg·h·mL-1 and that of the SD-2 pellet (which was designed to enhance drug release in intestinal fluids) was 7.50 ± 4.50 μg·h·mL-1. The AUC of the SD-2 pellet was 2.2 times higher than that of the SD-1 pellet. Based on pharmacokinetic data, ITZ would exist in a supersaturated state in the area of drug absorption. These results indicated that the absorption area is critical for improving the bioavailability of ITZ. Consequently, the bioavailability of ITZ could be improved by inhibiting precipitation in the absorption area.
Collapse
Affiliation(s)
- Ju-Hyun Lee
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea; (J.-H.L.); (C.-Y.K.)
| | - Chulhun Park
- Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada;
| | - Kwon-Yeon Weon
- College of Pharmacy, Catholic University of Daegu, Gyeongsan-si 38430, Korea;
| | - Chin-Yang Kang
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea; (J.-H.L.); (C.-Y.K.)
| | - Beom-Jin Lee
- College of Pharmacy, Ajou University, Suwon 16499, Korea;
| | - Jun-Bom Park
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea; (J.-H.L.); (C.-Y.K.)
- Bioavailability Control Lab, Sahmyook University, Seoul 01795, Korea
- Correspondence: ; Tel.: +82-2-3399-1624
| |
Collapse
|
7
|
Narayanan V, Alam M, Ahmad N, Balakrishnan SB, Ganesan V, Shanmugasundaram E, Rajagopal B, Thambusamy S. Electrospun poly (vinyl alcohol) nanofibers incorporating caffeic acid/cyclodextrins through the supramolecular assembly for antibacterial activity. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2021; 249:119308. [PMID: 33360058 DOI: 10.1016/j.saa.2020.119308] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 11/24/2020] [Accepted: 12/01/2020] [Indexed: 06/12/2023]
Abstract
Here, we prepared the solid inclusion complexes between Caffeic acid (CA) and Cyclodextrins (β- and γ-CDs) (CA/CDs) that were effectively embedded into Poly (vinyl alcohol) (PVA) electrospun nanofibers via electrospinning technique to enhanced solubility and antibacterial activity. In tested Cyclodextrins are β-and γ-CDs with CA in the ratio of 1:1 resulting in the formation of CA/CDs by co-precipitation method. The physical properties of CA/CDs were examined by FT-IR, UV, and Raman Spectroscopy. The phase solubility test showed a much higher solubility of CA due to inclusion complexes (ICs). Furthermore, CA/β-CD and CA/γ-CD perfected achieved 0.70:1 and 0.80:1 the molar ratio of ICs, confirmed by NMR studies. The fiber size distribution, average diameter, and morphology features were evaluated by SEM analysis. The dissolution profile of PVA/CA and PVA/CA/CDs were tested within 150 min, resulting in CA dissolved in PVA/CA/CDs slightly higher than PVA/CA nanofibers due to enhanced solubility of ICs. Moreover, PVA/CA/CDs exhibit high antibacterial activity against gram-positive bacteria of E-Coli and gram-negative bacteria of S. aureus. Finally, these results suggest that PVA/CA/CDs may be promising materials for active food packaging applications.
Collapse
Affiliation(s)
- Vimalasruthi Narayanan
- Department of Industrial Chemistry, Alagappa University, Karaikudi 630002, Tamil Nadu, India
| | - Manawwer Alam
- Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Naushad Ahmad
- Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | | | - Vigneshkumar Ganesan
- Department of Industrial Chemistry, Alagappa University, Karaikudi 630002, Tamil Nadu, India
| | | | - Brindha Rajagopal
- Department of Industrial Chemistry, Alagappa University, Karaikudi 630002, Tamil Nadu, India
| | - Stalin Thambusamy
- Department of Industrial Chemistry, Alagappa University, Karaikudi 630002, Tamil Nadu, India.
| |
Collapse
|
8
|
Arce FA, Setiawan N, Campbell HR, Lu X, Nethercott MJ, Bummer P, Su Y, Marsac PJ. Toward Developing Discriminating Dissolution Methods for Formulations Containing Nanoparticulates in Solution: The Impact of Particle Drift and Drug Activity in Solution. Mol Pharm 2020; 17:4125-4140. [PMID: 32965123 DOI: 10.1021/acs.molpharmaceut.0c00599] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Enabling formulations are an attractive approach to increase the dissolution rate, solubility, and oral bioavailability of poorly soluble compounds. With the growing prevalence of poorly soluble drug compounds in the pharmaceutical pipeline, supersaturating drug delivery systems (SDDS), a subset of enabling formulations, have grown in popularity due to their properties allowing for drug concentrations greater than the corresponding crystalline solubility. However, the extent of supersaturation generated as the enabling formulation traverses the gastrointestinal (GI) tract is dynamic and poorly understood. The dynamic nature of supersaturation is a result of several competing kinetic processes such as dissolution, solubilization by formulation and endogenous surfactants, crystallization, and absorption. Ultimately, the free drug concentration, which is equivalent to the drug's inherent thermodynamic activity amid these kinetic processes, defines the true driving force for drug absorption. However, in cases where solubilizing agents are present (i.e., surfactants and bile salts), drug molecules may associate with colloidal nanoscale species, complicating drug activity determination. These nanoscale species can drift into the aqueous boundary layer (ABL), increasing the local API activity at the membrane surface, resulting in increased bioavailability. Herein, a novel approach was developed to accurately measure thermodynamic drug activity in complex media containing drug distributed in nanoparticulate species. This approach captures the influence of the ABL on the observed flux and, ultimately, the predicted unbound drug concentration. The results demonstrate that this approach can help to (1) measure the true extent of local supersaturation in complex systems containing solubilizing excipients and (2) elucidate the mechanisms by which colloidal aggregates can modulate the drug activity in solution and potentially enhance the flux observed across a membrane. The utilization of these techniques may provide development scientists with a strategy to evaluate formulation sensitivity to nanospeciation and allow formulators to maximize the driving force for absorption in a complex environment, perhaps enabling the development of dissolution methods with greater discrimination and correlation to pre-clinical and clinical data sets.
Collapse
Affiliation(s)
- Freddy A Arce
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Nico Setiawan
- Albany Molecular Research Inc., West Lafayette, Indiana 47906, United States
| | - Heather R Campbell
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Xingyu Lu
- Pharmaceutical Sciences, Merck & Co., Kenilworth, New Jersey 07033, United States.,Key Laboratory of Precise Synthesis of Functional Molecules of Zhejiang Province, School of Science, Westlake University, Hangzhou, Zhejiang 310024, China
| | | | - Paul Bummer
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Yongchao Su
- Pharmaceutical Sciences, Merck & Co., Kenilworth, New Jersey 07033, United States.,Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States.,Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
| | - Patrick J Marsac
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States
| |
Collapse
|
9
|
Six years of progress in the oral biopharmaceutics area – A summary from the IMI OrBiTo project. Eur J Pharm Biopharm 2020; 152:236-247. [DOI: 10.1016/j.ejpb.2020.05.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 05/10/2020] [Indexed: 12/18/2022]
|
10
|
Suarez-Sharp S, Lindahl A, Heimbach T, Rostami-Hodjegan A, Bolger MB, Ray Chaudhuri S, Hens B. Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives. Pharm Res 2020; 37:95. [DOI: 10.1007/s11095-020-02814-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 04/02/2020] [Indexed: 12/12/2022]
|
11
|
O’Dwyer PJ, Imanidis G, Box KJ, Reppas C. On the Usefulness of Two Small-Scale In Vitro Setups in the Evaluation of Luminal Precipitation of Lipophilic Weak Bases in Early Formulation Development. Pharmaceutics 2020; 12:pharmaceutics12030272. [PMID: 32188116 PMCID: PMC7151110 DOI: 10.3390/pharmaceutics12030272] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 03/08/2020] [Accepted: 03/11/2020] [Indexed: 02/06/2023] Open
Abstract
A small-scale biphasic dissolution setup and a small-scale dissolution-permeation (D-P) setup were evaluated for their usefulness in simulating the luminal precipitation of three lipophilic weak bases—dipyridamole, ketoconazole and itraconazole. The transition from the gastric to intestinal environment was incorporated into both experimental procedures. Emulsification during the biphasic dissolution experiments had a minimal impact on the data, when appropriate risk mitigation steps were incorporated. Precipitation parameters estimated from the in vitro data were inputted into the Simcyp® physiologically based pharmacokinetic (PBPK) modelling software and simulated human plasma profiles were compared with previously published pharmacokinetic data. Average Cmax and AUC values estimated using experimentally derived precipitation parameters from the biphasic experiments deviated from corresponding published actual values less than values estimated using the default simulator parameters for precipitation. The slow rate of transport through the biomimetic membrane in the D-P setup limited its usefulness in forecasting the rates of in vivo precipitation used in the modelling of average plasma profiles.
Collapse
Affiliation(s)
- Patrick J. O’Dwyer
- Pion Inc. (UK) Ltd., Forest Row, East Sussex RH18 5DW, UK; (P.J.O.); (K.J.B.)
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, GR 157 84 Zografou, Greece
| | - Georgios Imanidis
- School of Life Sciences, Institute of Pharma Technology, University of Applied Sciences Northwestern Switzerland, Hofackerstrasse 30, 4132 Muttenz, Switzerland;
- Department of Pharmaceutical Sciences, University of Basel, CH 4056 Basel, Switzerland
| | - Karl J. Box
- Pion Inc. (UK) Ltd., Forest Row, East Sussex RH18 5DW, UK; (P.J.O.); (K.J.B.)
| | - Christos Reppas
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, GR 157 84 Zografou, Greece
- Correspondence: ; Tel.: +30-210-727-4678; Fax: +30-210-727-4027
| |
Collapse
|
12
|
Purohit HS, Trasi NS, Osterling DJ, Stolarik DF, Jenkins GJ, Gao W, Zhang GGZ, Taylor LS. Assessing the Impact of Endogenously Derived Crystalline Drug on the in Vivo Performance of Amorphous Formulations. Mol Pharm 2019; 16:3617-3625. [DOI: 10.1021/acs.molpharmaceut.9b00455] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Hitesh S. Purohit
- Department of Industrial & Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, Lafayette, Indiana 47907, United States
| | - Niraj S. Trasi
- Analytical Development, Celgene Corporation, 556 Morris Avenue, Summit, New Jersey 07901, United States
- Department of Industrial & Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, Lafayette, Indiana 47907, United States
| | | | | | | | | | | | - Lynne S. Taylor
- Department of Industrial & Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, Lafayette, Indiana 47907, United States
| |
Collapse
|
13
|
Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, Andreas CJ, Schaefer KJ, Mann J, McAllister M, Jamei M, Kostewicz E, Kesisoglou F, Langguth P, Minekus M, Müllertz A, Schilderink R, Koziolek M, Jedamzik P, Weitschies W, Reppas C, Augustijns P. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm 2019; 136:70-83. [DOI: 10.1016/j.ejpb.2018.12.010] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 12/19/2018] [Indexed: 02/08/2023]
|